Freeline Therapeutics Agrees to Buyout by Syncona

Dow Jones2023-11-22

By Colin Kellaher

Freeline Therapeutics Holdings has agreed to be acquired by majority shareholder Syncona in a deal that values the clinical-stage biotechnology company at about $28.3 million.

Freeline on Wednesday said a newly established portfolio company of life-science investor Syncona will pay $6.50 apiece for the Freeline American depositary shares Syncona doesn't already own.

The deal represents a 12% premium to Tuesday's closing price of $5.78 for Freeline and a more than 50% premium to the U.K. company's closing price on Oct. 17, before Syncona unveiled an initial bid of $5 per ADS.

Syncona currently owns nearly 58% of Freeline, which said it expects the takeover to close in the first quarter of 2024.

Trading in Freeline ADSs was halted premarket Wednesday.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

November 22, 2023 07:46 ET (12:46 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2385165997?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-11-22 20:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2385165997","market":"sg","top_or_hot":-1,"title":"Freeline Therapeutics Agrees to Buyout by Syncona","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Freeline Therapeutics Holdings has agreed to be acquired by majority shareholder Syncona in a deal that values the clinical-stage biotechnology company at about $28.3 million. \n</p>\n<p>\n  Freeline on Wednesday said a newly established portfolio company of life-science investor Syncona will pay $6.50 apiece for the Freeline American depositary shares Syncona doesn't already own. \n</p>\n<p>\n  The deal represents a 12% premium to Tuesday's closing price of $5.78 for Freeline and a more than 50% premium to the U.K. company's closing price on Oct. 17, before Syncona unveiled an initial bid of $5 per ADS. \n</p>\n<p>\n  Syncona currently owns nearly 58% of Freeline, which said it expects the takeover to close in the first quarter of 2024. \n</p>\n<p>\n  Trading in Freeline ADSs was halted premarket Wednesday. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 22, 2023 07:46 ET (12:46 GMT)\n</p>\n<p>\n  Copyright (c) 2023 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Freeline Therapeutics Agrees to Buyout by Syncona</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFreeline Therapeutics Agrees to Buyout by Syncona\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-11-22 20:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Colin Kellaher \n\n\n \n\n\n  Freeline Therapeutics Holdings has agreed to be acquired by majority shareholder Syncona in a deal that values the clinical-stage biotechnology company at about $28.3 ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FRLN","symbol_name":"Freeline Therapeutics Holdings plc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2385165997","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2385165997","pubTimestamp":1700657160,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Freeline Therapeutics Holdings has agreed to be acquired by majority shareholder Syncona in a deal that values the clinical-stage biotechnology company at about $28.3 million.Freeline on Wednesday said a newly established portfolio company of life-science investor Syncona will pay $6.50 apiece for the Freeline American depositary shares Syncona doesn't already own.The deal represents a 12% premium to Tuesday's closing price of $5.78 for Freeline and a more than 50% premium to the U.K. company's closing price on Oct. 17, before Syncona unveiled an initial bid of $5 per ADS.Syncona currently owns nearly 58% of Freeline, which said it expects the takeover to close in the first quarter of 2024.Trading in Freeline ADSs was halted premarket Wednesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FRLN":"Freeline Therapeutics Holdings plc","BK4139":"生物科技"},"translate_title":"Freeline Therapeutics同意Syncona收购","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FRLN":0.9},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Freeline Therapeutics Holdings has agreed to be acquired by majority shareholder Syncona in a deal that values the clinical-stage biotechnology company at about $28.3 million. \n\n\n  Freeline on Wednesday said a newly established portfolio company of life-science investor Syncona will pay $6.50 apiece for the Freeline American depositary shares Syncona doesn't already own. \n\n\n  The deal represents a 12% premium to Tuesday's closing price of $5.78 for Freeline and a more than 50% premium to the U.K. company's closing price on Oct. 17, before Syncona unveiled an initial bid of $5 per ADS. \n\n\n  Syncona currently owns nearly 58% of Freeline, which said it expects the takeover to close in the first quarter of 2024. \n\n\n  Trading in Freeline ADSs was halted premarket Wednesday. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 22, 2023 07:46 ET (12:46 GMT)\n\n\n  Copyright (c) 2023 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2385165997"}